|
|
|
|
The Medical House PLC 14 December 2005 ASI Disposable Autoinjector Project Agreement
The agreement requires that TMH develop and manufacture devices, according to defined operational and functional parameters, for technical assessment, over a projection duration of nine months. Under the terms of the agreement TMH will be reimbursed for all capital expenditure and the cost of associated design and development activities.
Ian Townsend, Executive Chairman, The Medical House PLC, said: "We are delighted to be involved in this very important
project. It provides further endorsement of the strength and flexibility
of the underlying ASI autoinjector platform technology as well
as TMH's ability to provide innovative solutions to meet our client'
requirements." For further information The Medical House PLC
About The Medical House - Market Background TMH has progressively been developing a range of needle-based and needle-free devices. The ASI AutoSafety Injector is TMH's needle-based disposable autoinjector technology. In June 2005 TMH announced a development and commercialisation agreement for the ASI disposable autoinjector technology with a subsidiary of a major global healthcare products group. In January 2005, TMH announced an agreement which it has signed with Serono, to develop and license a new needle-free delivery system for the delivery of Serono's Human Growth Hormone products. In February 2005 TMH announced a 10-year agreement which it has signed with BioPartners GmbH, to supply its GH1 needle-free system for the delivery of BioPartners' Human Growth Hormone products. The market for Human Growth Hormone drugs is expected to reach $2.2 billion by 2006 according to AS Insights. |
Site map
Privacy Statement | Copyright 2007 - The Medical House PLC. All rights reserved. | Terms of use | Top of page The Medical House PLC, 199 Newhall Road, Attercliffe, Sheffield,
S9 2QJ, UK. |
